Actualités

Novo Nordisk is playing catch-up in the GLP-1 race.

Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution of the compounded nasal spray in the Netherlands for infringing Novo Nordisk's semaglutide patent. The decision reinforces Novo Nordisk's intellectual property position around Wegovy, Ozempic and Rybelsus and limits non approved competitor versions. Patent enforcement around key obesity and diabetes...

The S&P 500 and Dow Jones hit highs while the Nasdaq raced above key levels as oil prices and yields fell. Palantir, Cloudflare and SpaceX were big movers amid earings.

Reporting 91% growth for Mounjaro, Lilly widened the gap to cardiometabolic rival Novo Nordisk.

Key takeawaysEli Lilly’s second-quarter revenue surged 48 per cent to US$22. 97 billion, beating Wall Street expectations by more than US$2 billion.

Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.

Novo Nordisk beats Q2 earnings and sales estimates as GLP-1 demand grows, but pricing pressure, outlook concerns and pipeline setbacks sent shares lower.

Eli Lilly and Novo Nordisk, the world’s two largest makers of weight-loss and diabetes drugs, raised their full-year forecasts on the back of...

Investing.com -- CVS Health shares jumped about 5% in premarket trading Wednesday after the company raised its full-year profit guidance following better-than-expected second-quarter results.

Aug 5 () - Eli Lilly and Co raised ‌its full-year revenue ‌forecast on Wednesday, banking ​on sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs. The ‌move comes ⁠less than a day after rival ⁠Novo Nordisk also hiked its full-year profit ​and sales ​forecast, ​banking on ‌its oral Wegovy pill to help claw back lost ground from Lilly in the lucrative ‌obesity market.

European stock indexes were rising at the open, extending a raft of record highs. Industrial and retail stocks jumped as the Europe-wide Stoxx 600 rises 0.5% to 659.75 points, a new record. London's FTSE 100 popped 0.

August 5 (Reuters) - European shares rose on Wednesday as investors monitored corporate earnings and diplomatic efforts to end the U.S.-Iran war and reopen the blockaded Strait of Hormuz.

The hospital chain raised almost $1 billion in India’s second-largest initial public offering so far this year.

Aug 5 () - India's Manipal Health Enterprises made its market debut at a 10.5% premium on Wednesday, valuing the ‌hospital chain at 857.

The Danish drugmaker's Wegovy pill has exceeded 5 million prescriptions in the U.S. since launch, driving stronger-than-expected profit

Earnings continue to be the market's engine, and a series of results this week from Palantir, SpaceX, and AMD are set to rev up stocks again.

Novo Nordisk and Eli Lilly compete in the same blockbuster drug class, yet their 2026 earnings tell dramatically different stories about which company holds the upper hand heading into a pivotal summer of reports and pricing resets.

Stocks rose in midday trading Friday, erasing earlier losses as investors assessed earnings from maj

They may profit from the rapidly growing GLP-1 market in very different ways.

Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.

With yields like this, these undervalued tickers aren't apt to remain this cheap forever.

All three can be bought on the dip.

Novo Nordisk (NYSE:NVO) received European Commission marketing authorization for its oral Wegovy pill for weight management. The approval covers the European Union and represents the first GLP-1 receptor agonist in pill form cleared for this use in the region. This decision follows growing use of obesity therapies in the U.S. and other key markets. Novo Nordisk is already a major player in diabetes and obesity care, and the oral Wegovy pill gives the company another way to reach patients...

PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth, acquisitions and a low valuation with a high dividend.

Oral Wegovy is now cleared in all EU member states.

Don't wait until clinical milestones send their share prices soaring.

Novo Nordisk presented long-term phase 3 data for denecimig (Mim8) prophylaxis in hemophilia patients, showing sustained efficacy, safety, and treatment satisfaction. The company also reported first efficacy and safety results for concizumab (Alhemo) in pediatric hemophilia patients under 12, indicating reduced bleeding and manageable safety. These trial readouts expand evidence across both adult and pediatric populations, supporting Novo Nordisk’s position in rare blood disorders. For...

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.

This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.

Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.